MASSACHUSETTS GENERAL HOSPITAL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1811-01-01
- Employees
- -
- Market Cap
- -
Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)
- Conditions
- CHFADHFControl
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06169540
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease
- Conditions
- Nonalcoholic Fatty Liver Disease
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06166797
The T1D Parent Check-In: A Preventative Intervention
- Conditions
- Type 1 DiabetesDiabetes in Children
- Interventions
- Behavioral: T1D Parent Check-in
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06160934
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Intervention Development for Syndemics Among PWH in SA
- Conditions
- HIV Infections
- Interventions
- Behavioral: Cognitive Behavioral Therapy for Syndemics and Adherence (CBT-SA)
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06152003
- Locations
- 🇿🇦
University of Cape Town, Cape Town, Western Cape, South Africa
Voice Therapy Per the Rehabilitation Treatment Specification System
- Conditions
- Muscle Tension Dysphonia
- Interventions
- Behavioral: Standard of care voice therapy with novice clinician RTSS-Voice documentationBehavioral: Standard of care voice therapy with expert clinician RTSS-Voice documentation
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT06152627
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸New York University, New York, New York, United States
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
- Conditions
- MelanomaNon-small Cell Lung Cancer
- Interventions
- Other: Evaluation of ctDNA using the F1T after 1 year of immunotherapy
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06146920
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Optimal Stimulation Parameters to Disrupt Epileptiform Activity
- Conditions
- Refractory Epilepsy
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06141668
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
- Conditions
- Depressive Disorder, MajorInflammation
- Interventions
- Other: Placebo
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06136546
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Elranatamab in R/R Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaRelapse Multiple MyelomaMultiple Myeloma
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06138275
- Locations
- 🇺🇸
Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Vaginal LIve Biotherapeutic RANdomized Trial
- Conditions
- Bacterial Vaginosis
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06135974
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇿🇦CAPRISA - Vulindlela, Msunduzi Municipality, KwaZulu Natal, South Africa